NCT05787197招募中不适用
Circulating Tumor DNA in Patients With Colorectal Cancer Undergoing Curative-intent Surgery for Liver Metastases: Prospective, Multicenter, GERCOR Cohort
GERCOR - Multidisciplinary Oncology Cooperative Group16 个研究点 分布在 1 个国家目标入组 232 人开始时间: 2024年1月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 232
- 试验地点
- 16
- 主要终点
- Disease-free survival (DFS) in patients who undergo curative-intent resection of colorectal liver metastasis (CRLM)
研究概览
简要总结
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of Colorectal cancer liver metastasis.
详细描述
Blood collection times according to specific clinical situations:
- Standard approach
- Combined surgery
- Reverse strategy
- Two-stage hepatectomy
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Disease-free survival (DFS) in patients who undergo curative-intent resection of colorectal liver metastasis (CRLM)
时间窗: Up to 36 months
DFS is defined as the time from complete surgical resection (following first surgery if one-stage surgery or second surgery if two-stage strategy) to first documented event (relapse or death, whichever occurred first), or until last contact if no event occurs.
次要结局
- Prognostic factor(s) for disease recurrence and survival.(Up to 4 years)
- Number of event-free survival (EFS) in patients who undergo curative-intent resection of CRLM.(Up to 4 years)
- Overall survival (OS) n patients who undergo curative-intent resection of CRLM.(Up to 4 years)
- Prognostic value of ctDNA(Up to 4 years)
- Association between ctDNA and clinical features.(Up to 4 years)
- Time to surgical failure (TSF) in patients who undergo curative-intent resection of CRLM.(Up to 4 years)
研究者
研究点 (16)
Loading locations...
相似试验
进行中（未招募）
不适用
Use of ctDNA for Monitoring of Stage III Colorectal CancerStage III Colorectal CancerNCT02842203University of Pittsburgh137
进行中（未招募）
不适用
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLCAdvanced Lung Non-Small Cell CarcinomaNCT05198154Fang Wu100
已完成
不适用
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast CancerCirculating Tumor DNAGene AbnormalityMetastatic Breast CancerNCT05427617Hunan Cancer Hospital223
已完成
不适用
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast CancerCirculating Tumor DNAGene AbnormalityMetastatic Breast CancerNCT05079074Hunan Cancer Hospital223
进行中（未招募）
不适用
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant TumorEarly Detection of CancerNCT04405557Geneplus-Beijing Co. Ltd.757